These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2339414)

  • 1. Pharmacokinetics of [125I]-2-iodo-3,7,8-trichlorodibenzo-p-dioxin in mice: analysis with a physiological modeling approach.
    Leung HW; Poland A; Paustenbach DJ; Murray FJ; Andersen ME
    Toxicol Appl Pharmacol; 1990 May; 103(3):411-9. PubMed ID: 2339414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A physiological pharmacokinetic description of the tissue distribution and enzyme-inducing properties of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat.
    Leung HW; Paustenbach DJ; Murray FJ; Andersen ME
    Toxicol Appl Pharmacol; 1990 May; 103(3):399-410. PubMed ID: 2160135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A physiologically based pharmacokinetic model for 2,3,7,8-tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice.
    Leung HW; Ku RH; Paustenbach DJ; Andersen ME
    Toxicol Lett; 1988 Jul; 42(1):15-28. PubMed ID: 2838936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disposition of 2,3,7,8-tetrabromodibenzo-p-dioxin and 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat: biliary excretion and induction of cytochromes CYP1A1 and CYP1A2.
    Kedderis LB; Diliberto JJ; Linko P; Goldstein JA; Birnbaum LS
    Toxicol Appl Pharmacol; 1991 Oct; 111(1):163-72. PubMed ID: 1949032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of in vivo hepatic uptake and in vitro hepatic binding of [125I]2-lodo-3,7,8-trichlorodibenzo-p-dioxin by the administration of agonist for the Ah receptor.
    Poland A; Teitelbaum P; Glover E; Kende A
    Mol Pharmacol; 1989 Jul; 36(1):121-7. PubMed ID: 2546046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue distribution after a single subcutaneous administration of 2,3,7,8-tetrabromodibenzo-p-dioxin in comparison with toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Wistar rats.
    Nagao T; Yamashita K; Golor G; Bittmann H; Körner W; Hagenmaier H; Neubert D
    Life Sci; 1996; 58(4):325-36. PubMed ID: 8538369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and biological activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. 1. Dose-dependent tissue distribution and induction of hepatic ethoxyresorufin O-deethylase in rats following a single injection.
    Abraham K; Krowke R; Neubert D
    Arch Toxicol; 1988; 62(5):359-68. PubMed ID: 3242446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [125I]2-iodo-3,7,8-trichlorodibenzo-p-dioxin-binding species in mouse liver induced by agonists for the Ah receptor: characterization and identification.
    Poland A; Teitelbaum P; Glover E
    Mol Pharmacol; 1989 Jul; 36(1):113-20. PubMed ID: 2546045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,3,7,8-Tetrachlorodibenzo-p-dioxin pretreatment of female mice altered tissue distribution but not hepatic metabolism of a subsequent dose.
    Curtis LR; Kerkvliet NI; Baecher-Steppan L; Carpenter HM
    Fundam Appl Toxicol; 1990 Apr; 14(3):523-31. PubMed ID: 2340981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapolation of a PBPK model for dioxins across dosage regimen, gender, strain, and species.
    Wang X; Santostefano MJ; DeVito MJ; Birnbaum LS
    Toxicol Sci; 2000 Jul; 56(1):49-60. PubMed ID: 10869453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD): assessing the impact of specific model parameters on sequestration in liver and fat in the rat.
    Evans MV; Andersen ME
    Toxicol Sci; 2000 Mar; 54(1):71-80. PubMed ID: 10746933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of 2,2',4,4',5,5'-hexachlorobiphenyl cotreatment on the disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice.
    De Jongh J; DeVito M; Diliberto J; Van den Berg M; Birnbaum L
    Toxicol Lett; 1995 Oct; 80(1-3):131-7. PubMed ID: 7482580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dose on 2,3,7,8-TCDD tissue distribution, metabolism and elimination in CYP1A2 (-/-) knockout and C57BL/6N parental strains of mice.
    Hakk H; Diliberto JJ; Birnbaum LS
    Toxicol Appl Pharmacol; 2009 Nov; 241(1):119-26. PubMed ID: 19695277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP technical report on the toxicology and carcinogenesis studies of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (CAS No. 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2006 Apr; (521):4-232. PubMed ID: 16835633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between the murine Ah phenotype and the hepatic uptake and metabolism of 2,3,7,8-tetrachlorodibenzo-p-dioxin.
    Shen ES; Olson JR
    Drug Metab Dispos; 1987; 15(5):653-60. PubMed ID: 2891482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dose, time, and pretreatment on the biliary excretion and tissue distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat.
    Kedderis LB; Andersen ME; Birnbaum LS
    Fundam Appl Toxicol; 1993 Nov; 21(4):405-11. PubMed ID: 8253293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A physiologically based pharmacokinetic model for 2,3,7,8-tetrabromodibenzo-p-dioxin (TBDD) in the rat: tissue distribution and CYP1A induction.
    Kedderis LB; Mills JJ; Andersen ME; Birnbaum LS
    Toxicol Appl Pharmacol; 1993 Jul; 121(1):87-98. PubMed ID: 8337704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative distribution of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human hepatic and adipose tissues.
    Leung HW; Wendling JM; Orth R; Hileman F; Paustenbach DJ
    Toxicol Lett; 1990 Feb; 50(2-3):275-82. PubMed ID: 2309246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative dermal absorption of 2,3,7,8-tetrachlorodibenzo-p-dioxin and three polychlorinated dibenzofurans.
    Brewster DW; Banks YB; Clark AM; Birnbaum LS
    Toxicol Appl Pharmacol; 1989 Jan; 97(1):156-66. PubMed ID: 2916232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD.
    Emond C; Birnbaum LS; DeVito MJ
    Environ Health Perspect; 2006 Sep; 114(9):1394-400. PubMed ID: 16966094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.